Skip to main content

Table 1 ECP level in biological fluids and tissues

From: Analysing the eosinophil cationic protein - a clue to the function of the eosinophil granulocyte

Biological Fluid ECP concentration (ng/mL) Eosinophils (×10 6)/mL
Plasma
   Normal value 3.5 0.104 (±0.033) [112]
   Ongoing asthma/allergy 3.5 N/A [43]
   S. mansoni infection 27 0.4 (0.2-0.8) [156]
   Reactive eosinophilia with a inflammation 75 1.9 (±3.2) [112]
   HES 243 19.9 (±10.9) [112]
Serum
   Normal value 7 N/A
   Ongoing allergy/asthma 15 N/A [43]
   S. mansoni infection ~62 0.163
   Atopic Dermatitis inflammation ~50 0.315
   Bacterial infection ~19 N/A [72]
   HES 45- 198 22-58 percent of total cells [111]
   Renal tumour ~30 N/A [123]
BALF
   Normal value ~4 0.2 (±0.1)
   Atopic asthma (challenged) ~40 55.0 (±34.3) [97]
   Drug-induced ARDS 13.8 4 percent of total cells [78]
Sputum
   Normal value 95 0.2 percent of total cells
   Asthma 735 13.4 percent of total cells
   Eosinophil bronchitis 604 12.4 percent of total cells [157]
   Experimental Viral Day -5 119.1 (8.9-1,146) 9.3 (0-30.3) percent of total cells
   Rhinovirus infection Day 2 190.6 (17.2-800) b) 7.5 (0.1-34.4) percent of total cells
   Day 9 157.9(27.8-800) 5.5 (0.4-23.3) percent of total cells [136]
Nasal lavage
   Normal value 3-31 N/A [158]
   Allergic rhinitis 9 ± 2.4 19 (±2.1) percent of total cells
   Allergic rhinitis 6 hr after allergen challenge 36.6 ± 12 56.7 (±5.8) percent of total cells [159]
Nasal secretions
   Normal value 56.2 (33.5-94.2)  
   RSV infection 379 (269-532) [75]  
   Natural cold 13038  
   Severe community acquired bacterial sinusitis 117 704 [77]  
Tears
   Normal value <20 1 (±0.2) cells/mm2 in subepithelium [160]
   Atopic keratoconjunctivitis 215 (36-1900) [161] N/A
   Vernal keratoconjunctivitis 470 (19-6000) [161] 112 (±37) cells/mm2 in subepithelium [160]
Skin, cutaneous
   Normal N/A  
   Atopic dermatitis >16 000 [64]  
  1. ECP measurements in various biological fluids. Type of fluid, concentration of ECP measured and number of eosinophils are presented.
  2. a) Patients with asthma, atopic dermatitis, lung disease, GI diseases, idiopathic/autoimmune inflammatory conditions
  3. b) Statistically significant increase